Search

Your search keyword '"Gastaud, Lauris"' showing total 308 results
Start Over Author "Gastaud, Lauris"
308 results on '"Gastaud, Lauris"'

1. Publisher Correction: LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition

Author

Proteau, Sarah, Krossa, Imène, Husser, Chrystel, Guéguinou, Maxime, Sella, Federica, Bille, Karine, Irondelle, Marie, Dalmasso, Mélanie, Barouillet, Thibault, Cheli, Yann, Pisibon, Céline, Arrighi, Nicole, Nahon-Estève, Sacha, Martel, Arnaud, Gastaud, Lauris, Lassalle, Sandra, Mignen, Olivier, Brest, Patrick, Mazure, Nathalie M, Bost, Frédéric, Baillif, Stéphanie, Landreville, Solange, Turcotte, Simon, Hasson, Dan, Carcamo, Saul, Vandier, Christophe, Bernstein, Emily, Yvan-Charvet, Laurent, Levesque, Mitchell P, Ballotti, Robert, Bertolotto, Corine, and Strub, Thomas

Published
2024
Full Text
View/download PDF

2. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.

Author

Hassel, Jessica, Piperno-Neumann, Sophie, Rutkowski, Piotr, Baurain, Jean-Francois, Schlaak, Max, Butler, Marcus, Sullivan, Ryan, Dummer, Reinhard, Kirkwood, John, Orloff, Marlana, Sacco, Joseph, Ochsenreither, Sebastian, Joshua, Anthony, Gastaud, Lauris, Curti, Brendan, Piulats, Josep, Salama, April, Shoushtari, Alexander, Demidov, Lev, Milhem, Mohammed, Chmielowski, Bartosz, Kim, Kevin, Carvajal, Richard, Hamid, Omid, Collins, Laura, Ranade, Koustubh, Holland, Chris, Pfeiffer, Constance, and Nathan, Paul

Subjects
Adult, Humans, Antineoplastic Combined Chemotherapy Protocols, HLA-A Antigens, Melanoma, Uveal Neoplasms, Recombinant Fusion Proteins
Abstract

BACKGROUND: Tebentafusp, a T-cell receptor-bispecific molecule that targets glycoprotein 100 and CD3, is approved for adult patients who are positive for HLA-A*02:01 and have unresectable or metastatic uveal melanoma. The primary analysis in the present phase 3 trial supported a long-term survival benefit associated with the drug. METHODS: We report the 3-year efficacy and safety results from our open-label, phase 3 trial in which HLA-A*02:01-positive patients with previously untreated metastatic uveal melanoma were randomly assigned in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigators choice of therapy with pembrolizumab, ipilimumab, or dacarbazine (control group), with randomization stratified according to the lactate dehydrogenase level. The primary end point was overall survival. RESULTS: At a minimum follow-up of 36 months, median overall survival was 21.6 months in the tebentafusp group and 16.9 months in the control group (hazard ratio for death, 0.68; 95% confidence interval, 0.54 to 0.87). The estimated percentage of patients surviving at 3 years was 27% in the tebentafusp group and 18% in the control group. The most common treatment-related adverse events of any grade in the tebentafusp group were rash (83%), pyrexia (76%), pruritus (70%), and hypotension (38%). Most tebentafusp-related adverse events occurred early during treatment, and no new adverse events were observed with long-term administration. The percentage of patients who discontinued treatment because of adverse events continued to be low in both treatment groups (2% in the tebentafusp group and 5% in the control group). No treatment-related deaths occurred. CONCLUSIONS: This 3-year analysis supported a continued long-term benefit of tebentafusp for overall survival among adult HLA-A*02:01-positive patients with previously untreated metastatic uveal melanoma. (Funded by Immunocore; IMCgp100-202 ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).

Published
2023

4. A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.

Author

Daver, Naval Guastad, primary, Montesinos, Pau, additional, Altman, Jessica K., additional, Advani, Anjali S., additional, Wang, Eunice S., additional, Garciaz, Sylvain, additional, Martinelli, Giovanni, additional, Roboz, Gail J., additional, Walter, Roland B., additional, Begna, Kebede, additional, Lunghi, Monia, additional, Platzbecker, Uwe, additional, Vyas, Paresh, additional, Burke, Patrick William, additional, Curti, Antonio, additional, DeAngelo, Daniel J., additional, Gastaud, Lauris, additional, Schliemann, Christoph, additional, Oshrine, Benjamin, additional, and Sallman, David Andrew, additional

Published
2024
Full Text
View/download PDF

5. MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients

Author

Saint-Ghislain, Mathilde, Derrien, Anne-Céline, Geoffrois, Lionnel, Gastaud, Lauris, Lesimple, Thierry, Negrier, Sylvie, Penel, Nicolas, Kurtz, Jean-Emmanuel, Le Corre, Yannick, Dutriaux, Caroline, Gardrat, Sophie, Barnhill, Raymond, Matet, Alexandre, Cassoux, Nathalie, Houy, Alexandre, Ramtohul, Toulsie, Servois, Vincent, Mariani, Pascale, Piperno-Neumann, Sophie, Stern, Marc-Henri, and Rodrigues, Manuel

Published
2022
Full Text
View/download PDF

6. Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group

Author

Michallet, Mauricette, Sobh, Mohamad, Morisset, Stephane, Deloire, Alexandre, Raffoux, Emmanuel, de Botton, Stephane, Caillot, Denis, Chantepie, Sylvain, Girault, Stephane, Berthon, Celine, Bertoli, Sarah, Lepretre, Stephane, Leguay, Thibaut, Castaigne, Sylvie, Marolleau, Jean-Pierre, Pautas, Cecile, Malfuson, Jean-Valere, Veyn, Norbert, Braun, Thorsten, Gastaud, Lauris, Suarez, Felipe, Schmidt, Aline, Gressin, Remy, Bonmati, Caroline, Celli-Lebras, Karine, El-Hamri, Mohamed, Ribaud, Patricia, Dombret, Herve, Thomas, Xavier, and Bergeron, Anne

Published
2022
Full Text
View/download PDF

7. Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Author

Garderet, Laurent, primary, Gras, Luuk, additional, Koster, Linda, additional, De Wreede, Liesbeth, additional, Montserrat, Rovira, additional, Vincent, Laure, additional, Fenk, Roland, additional, Karunanithi, Kamaraj, additional, Deeren, Dries, additional, Kaufmann, Martin, additional, Kuball, Jürgen, additional, Ozdogu, Hakan, additional, Cascon, Maria Jesus Pascual, additional, Passweg, Jakob, additional, Rye, Adam, additional, Salmenniemi, Urpu, additional, Snowden, John, additional, Hansen, Charlotte Toftmann, additional, Leleu, Xavier, additional, Gastaud, Lauris, additional, Sokolowska, Joanna Drozd, additional, Raj, Kavita, additional, Beksac, Meral, additional, Schönland, Stefan, additional, Hayden, Patrick, additional, and McLornan, Donal, additional

Published
2024
Full Text
View/download PDF

10. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

Author

Gardin, Claude, Pautas, Cécile, Fournier, Elise, Itzykson, Raphaël, Lemasle, Emilie, Bourhis, Jean-Henri, Adès, Lionel, Marolleau, Jean-Pierre, Malfuson, Jean-Valère, Gastaud, Lauris, Raffoux, Emmanuel, Lambert, Juliette, Braun, Thorsten, Thomas, Xavier, Chantepie, Sylvain, Cluzeau, Thomas, de Botton, Stéphane, Berthon, Céline, Boissel, Nicolas, Duployez, Nicolas, Terré, Christine, Peffault de Latour, Régis, Michallet, Mauricette, Celli-Lebras, Karine, Preudhomme, Claude, and Dombret, Hervé

Published
2020
Full Text
View/download PDF

12. LKB1‐SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition

Author

Proteau, Sarah, primary, Krossa, Imène, additional, Husser, Chrystel, additional, Guéguinou, Maxime, additional, Sella, Federica, additional, Bille, Karine, additional, Irondelle, Marie, additional, Dalmasso, Mélanie, additional, Barouillet, Thibault, additional, Cheli, Yann, additional, Pisibon, Céline, additional, Arrighi, Nicole, additional, Nahon‐Estève, Sacha, additional, Martel, Arnaud, additional, Gastaud, Lauris, additional, Lassalle, Sandra, additional, Mignen, Olivier, additional, Brest, Patrick, additional, Mazure, Nathalie M, additional, Bost, Frédéric, additional, Baillif, Stéphanie, additional, Landreville, Solange, additional, Turcotte, Simon, additional, Hasson, Dan, additional, Carcamo, Saul, additional, Vandier, Christophe, additional, Bernstein, Emily, additional, Yvan‐Charvet, Laurent, additional, Levesque, Mitchell P, additional, Ballotti, Robert, additional, Bertolotto, Corine, additional, and Strub, Thomas, additional

Published
2023
Full Text
View/download PDF

14. AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions

Author

Daver, Naval, Montesinos, Pau, Aribi, Ahmed, Martinelli, Giovanni, Altman, Jessica K., Wang, Eunice S., Roboz, Gail J., Burke, Patrick W., Gaidano, Gianluca, Walter, Roland B., Thomas, Xavier, Jeyakumar, Deepa, DeAngelo, Daniel J., Erba, Harry P., Todisco, Elisabetta, Begna, Kebede, Advani, Anjali, Gastaud, Lauris, de la Fuente, Adolfo, Curti, Antonio, Mendez, Lourdes M., Vyas, Paresh, Boissel, Nicolas, Vey, Norbert, Recher, Christian, Longval, Thomas, Platzbecker, Uwe, Kapp-Schwörer, Silke, Schliemann, Christoph, Konopleva, Marina, Torres, Laura, Sallman, David A., Marcucci, Guido, Marconi, Giovanni, Kantarjian, Hagop, Sloss, Callum M., Malcolm, Karen E., Zweidler-McKay, Patrick A., and Sweet, Kendra

Published
2022
Full Text
View/download PDF

16. Assessment of Different Circulating Tumor Cell Platforms for Uveal Melanoma: Potential Impact for Future Routine Clinical Practice

Author

Martel, Arnaud, primary, Mograbi, Baharia, additional, Romeo, Barnabe, additional, Gastaud, Lauris, additional, Lalvee, Salome, additional, Zahaf, Katia, additional, Fayada, Julien, additional, Nahon-Esteve, Sacha, additional, Bonnetaud, Christelle, additional, Salah, Myriam, additional, Tanga, Virginie, additional, Baillif, Stéphanie, additional, Bertolotto, Corine, additional, Lassalle, Sandra, additional, and Hofman, Paul, additional

Published
2023
Full Text
View/download PDF

18. Single-masked Randomized Phase II Study Assessing Two Forms of Hypofractionated Proton Therapy in Patients with Large Choroidal Melanomas

Author

THARIAT, Juliette, primary, MATHIS, Thibaud, additional, PACE-LOSCOS, Tanguy, additional, PEYRICHON, Marie Laure, additional, MASCHI, Celia, additional, ROSIER, Laurence, additional, NGUYEN, Minh, additional, BONNIN, Nicolas, additional, ALOI, Deborah, additional, GASTAUD, Lauris, additional, GAUCHER, David, additional, CAUJOLLE, Jean-Pierre, additional, CHÂTEAU, Yann, additional, and HERAULT, Joel, additional

Published
2023
Full Text
View/download PDF

19. Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study

Author

Talbot, Alexis, primary, Bobin, Arthur, additional, Tabone, Léa, additional, Lambert, Jérôme, additional, Boccaccio, Catherine, additional, Deal, Cécile, additional, Petillon, Marie-Odile, additional, Allangba, Olivier, additional, Agape, Philippe, additional, Arnautou, Pierre, additional, Belkhir, Rakiba, additional, Cailleres, Sylvie, additional, Chaoui, Driss, additional, Chrétien, Marie-Lorraine, additional, Decaux, Olivier, additional, Schulmann, Samantha, additional, Frenzel, Laurent, additional, Gastaud, Lauris, additional, Huart, Antoine, additional, Hulin, Cyrille, additional, Karlin, Lionel, additional, Laribi, Kamel, additional, Le Calloch, Ronan, additional, Lenain, Pascal, additional, Macro, Margaret, additional, Manier, Salomon, additional, Montes, Lydia, additional, Moreau, Stéphane, additional, Moreau, Philippe, additional, Morel, Véronique, additional, Norwood, James, additional, Piocelle, Frédérique Orsini, additional, Perrot, Aurore, additional, Pica, Gian Matteo, additional, Rey, Philippe, additional, Schmitt, Anna, additional, Stoppa, Anne-Marie, additional, Tiab, Mourad, additional, Touzeau, Cyrille, additional, Vidal, Valérie, additional, Vignon, Marguerite, additional, Vincent, Laure, additional, Van De Wyngaert, Zoé, additional, Zarnitsky, Charles, additional, Kerbouche, Naima, additional, Paka, Prani, additional, Leleu, Xavier, additional, Arnulf, Bertrand, additional, Avet-Loiseau, Hervé, additional, and Du Myélome, IFM: Intergroupe Francophone, additional

Published
2023
Full Text
View/download PDF

21. Need for a Dedicated Ophthalmic Malignancy Clinico-Biological Biobank: The Nice Ocular MAlignancy (NOMA) Biobank

Author

Martel, Arnaud, primary, Gastaud, Lauris, additional, Bonnetaud, Christelle, additional, Nahon-Esteve, Sacha, additional, Washetine, Kevin, additional, Bordone, Olivier, additional, Salah, Myriam, additional, Tanga, Virginie, additional, Fayada, Julien, additional, Lespinet, Virginie, additional, Allegra, Maryline, additional, Lalvee, Salome, additional, Zahaf, Katia, additional, Baillif, Stephanie, additional, Bertolotto, Corine, additional, Mograbi, Baharia, additional, Lassalle, Sandra, additional, and Hofman, Paul, additional

Published
2023
Full Text
View/download PDF

22. Data from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

31. In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations

Author

Lannes, Romain, primary, Samur, Mehmet, additional, Perrot, Aurore, additional, Mazzotti, Celine, additional, Divoux, Marion, additional, Cazaubiel, Titouan, additional, Leleu, Xavier, additional, Schavgoulidze, Anaïs, additional, Chretien, Marie-Lorraine, additional, Manier, Salomon, additional, Adiko, Didier, additional, Orsini-Piocelle, Frederique, additional, Lifermann, François, additional, Brechignac, Sabine, additional, Gastaud, Lauris, additional, Bouscary, Didier, additional, Macro, Margaret, additional, Cleynen, Alice, additional, Mohty, Mohamad, additional, Munshi, Nikhil, additional, Corre, Jill, additional, and Avet-Loiseau, Hervé, additional

Published
2023
Full Text
View/download PDF

32. Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Author

Daver, Naval, primary, Montesinos, Pau, additional, Aribi, Ahmed, additional, Marconi, Giovanni, additional, Altman, Jessica K., additional, Wang, Eunice S., additional, Roboz, Gail J., additional, Burke, Patrick W., additional, Gaidano, Gianluca, additional, Walter, Roland B., additional, Thomas, Xavier, additional, Jeyakumar, Deepa, additional, DeAngelo, Daniel J., additional, Erba, Harry P., additional, Todisco, Elisabetta, additional, Begna, Kebede H., additional, Advani, Anjali, additional, Gastaud, Lauris, additional, De La Fuente, Adolfo, additional, Curti, Antonio, additional, Mendez, Lourdes M., additional, Vyas, Paresh, additional, Boissel, Nicolas, additional, Vey, Norbert, additional, Recher, Christian, additional, Longval, Thomas, additional, Platzbecker, Uwe, additional, Kapp-Schwoerer, Silke, additional, Schliemann, Christoph, additional, Konopleva, Marina, additional, Torres, Laura, additional, Sallman, David A., additional, Marcucci, Guido, additional, Pemmaraju, Naveen, additional, Martinelli, Giovanni, additional, Kantarjian, Hagop, additional, Sloss, Callum M, additional, Malcolm, Kara E, additional, Zweidler-McKay, Patrick A, additional, and Sweet, Kendra, additional

Published
2022
Full Text
View/download PDF

33. Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, additional, Garciaz, Sylvain, additional, Etienne, Gabriel, additional, Belhabri, Amine, additional, Bertoli, Sarah, additional, Gastaud, Lauris, additional, Simand, Celestine, additional, Chantepie, Sylvain, additional, Uzunov, Madalina, additional, Genthon, Alexis, additional, Berthon, Celine, additional, Chiche, Edmond, additional, Dumas, Pierre-Yves, additional, Vargaftig, Jacques, additional, Salmeron, Géraldine, additional, Lemasle, Emilie, additional, Tavernier, Emmanuelle, additional, Delage, Jeremy, additional, Loirat, Marion, additional, Morineau, Nadine, additional, Blanc-Durand, Felix, additional, Pautier, Patricia, additional, Vergé, Veronique, additional, Auger, Nathalie, additional, Thomas, Myrtille, additional, Stefani, Laetitia, additional, Lepelley, Marion, additional, Boyer, Thomas, additional, Thepot, Sylvain, additional, Gourin, Marie-Pierre, additional, Bourquard, Pascal, additional, Duchmann, Matthieu, additional, Morice, Pierre, additional, Michallet, Mauricette, additional, Ades, Lionel, additional, Fenaux, Pierre, additional, Recher, Christian, additional, Dombret, Hervé, additional, Pages, Arnaud, additional, Marzac, Christophe, additional, Leary, Alexandra, additional, and Micol, Jean-Baptiste, additional

Published
2022
Full Text
View/download PDF

34. Poster: AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions

Author

Daver, Naval, primary, Montesinos, Pau, additional, Aribi, Ahmed, additional, Martinelli, Giovanni, additional, Altman, Jessica K., additional, Wang, Eunice S., additional, Roboz, Gail J., additional, Burke, Patrick W., additional, Gaidano, Gianluca, additional, Walter, Roland B., additional, Thomas, Xavier, additional, Jeyakumar, Deepa, additional, DeAngelo, Daniel J., additional, Erba, Harry P., additional, Todisco, Elisabetta, additional, Begna, Kebede, additional, Advani, Anjali, additional, Gastaud, Lauris, additional, de la Fuente, Adolfo, additional, Curti, Antonio, additional, Mendez, Lourdes M., additional, Vyas, Paresh, additional, Boissel, Nicolas, additional, Vey, Norbert, additional, Recher, Christian, additional, Longval, Thomas, additional, Platzbecker, Uwe, additional, Kapp-Schwörer, Silke, additional, Schliemann, Christoph, additional, Konopleva, Marina, additional, Torres, Laura, additional, Sallman, David A., additional, Marcucci, Guido, additional, Marconi, Giovanni, additional, Kantarjian, Hagop, additional, Sloss, Callum M., additional, Malcolm, Karen E., additional, Zweidler-McKay, Patrick A., additional, and Sweet, Kendra, additional

Published
2022
Full Text
View/download PDF

35. OAB-016: High risk subclones detected at relapse are present from diagnosis in small subclones and impact the prognosis

Author

Lannes, Romain, primary, Samur, Mehmet, additional, Perrot, Aurore, additional, Mazzotti, Celine, additional, Divoux, Marion, additional, Cazaubiel, Titouan, additional, Schavgoulidze, Anaïs, additional, Chretien, Marie-Lorraine, additional, Manier, Salomon, additional, Adiko, Didier, additional, Orsini-Piocelle, Frederique, additional, Lifermann, François, additional, Brechignac, Sabine, additional, Gastaud, Lauris, additional, Bouscary, Didier, additional, Macro, Margaret, additional, Cleynen, Alice, additional, Mohty, Mohamad, additional, Munshi, Nikhil, additional, Corre, Jill, additional, and Avet-Loiseau, Hervé, additional

Published
2022
Full Text
View/download PDF

36. Early together: A randomized phase III study of early palliative care in metastatic uveal melanoma (MUM).

Author

Piperno-Neumann, Sophie, primary, Rodrigues, Manuel, additional, Marchal, Timothee, additional, Gastaud, Lauris, additional, Fogliarini, Anne, additional, Bouleuc, Carole, additional, Libert, Yves, additional, de Koning, Leanne, additional, Bredart, Anne, additional, Savignoni, Alexia, additional, Dolbeault, Sylvie, additional, and Burnod, Alexis, additional

Published
2022
Full Text
View/download PDF

37. MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients: A retrospective study.

Author

Saint-Ghislain, Mathilde, primary, Geoffrois, Lionnel, additional, Gastaud, Lauris, additional, Lesimple, Thierry, additional, Negrier, Sylvie, additional, Penel, Nicolas, additional, Kurtz, Jean Emmanuel, additional, Le Corre, Yannick, additional, Dutriaux, Caroline, additional, Gardrat, Sophie, additional, Barnhill, Raymond, additional, Matet, Alexandre, additional, Cassoux, Nathalie, additional, Ramtohul, Toulsie, additional, Servois, Vincent, additional, Mariani, Pascale, additional, Piperno-Neumann, Sophie, additional, and Rodrigues, Manuel, additional

Published
2022
Full Text
View/download PDF

39. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

Author

Castaigne, Sylvie, Pautas, Cécile, Terré, Christine, Raffoux, Emmanuel, Bordessoule, Dominique, Bastie, Jean-Noel, Legrand, Ollivier, Thomas, Xavier, Turlure, Pascal, Reman, Oumedaly, de Revel, Thierry, Gastaud, Lauris, de Gunzburg, Noémie, Contentin, Nathalie, Henry, Estelle, Marolleau, Jean-Pierre, Aljijakli, Ahmad, Rousselot, Philippe, Fenaux, Pierre, Preudhomme, Claude, Chevret, Sylvie, and Dombret, Hervé

Published
2012
Full Text
View/download PDF

40. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Author

Nathan, Paul, Hassel, Jessica C, Rutkowski, Piotr, Baurain, Jean-Francois, Butler, Marcus O, Schlaak, Max, Sullivan, Ryan J, Ochsenreither, Sebastian, Dummer, Reinhard, Kirkwood, John M, Joshua, Anthony M, Sacco, Joseph J, Shoushtari, Alexander N, Orloff, Marlana, Piulats, Josep M, Milhem, Mohammed, Salama, April KS, Curti, Brendan, Demidov, Lev, Gastaud, Lauris, Mauch, Cornelia, Yushak, Melinda, Carvajal, Richard D, Hamid, Omid, Abdullah, Shaad E, Holland, Chris, Goodall, Howard, Piperno-Neumann, Sophie, Investigators, IMCgp100-202, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, and UCL - (SLuc) Unité d'oncologie médicale

Subjects
Adult, Male, Uveal Neoplasms, Oncology, medicine.medical_specialty, Recombinant Fusion Proteins, MEDLINE, Antineoplastic Agents, Disease, Therapeutics, Antibodies, Monoclonal, Humanized, law.invention, Randomized controlled trial, law, Internal medicine, medicine, Humans, Càncer, Melanoma, neoplasms, Survival analysis, Aged, Cancer, Aged, 80 and over, business.industry, General Medicine, Exanthema, Middle Aged, Ophthalmopathies, medicine.disease, Terapèutica, Ipilimumab, Survival Analysis, eye diseases, Dacarbazine, Clinical trial, Cutaneous melanoma, Monoclonal, Female, Cytokine Release Syndrome, business, Oftalmopaties
Abstract

Background: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. Methods: In this open-label, phase 3 trial, we randomly assigned previously untreated HLA-A*02:01-positive patients with metastatic uveal melanoma in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified according to the lactate dehydrogenase level. The primary end point was overall survival. Results: A total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control group (126 patients). Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P

Published
2021

42. A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Author

Daver, Naval, primary, Aribi, Ahmed, additional, Montesinos, Pau, additional, Roboz, Gail J., additional, Wang, Eunice S., additional, Walter, Roland B., additional, Jeyakumar, Deepa, additional, DeAngelo, Daniel J., additional, Erba, Harry P., additional, Advani, Anjali, additional, Burke, Patrick W., additional, Martinelli, Giovanni, additional, Gastaud, Lauris, additional, Thomas, Xavier, additional, Altman, Jessica K., additional, Mendez, Lourdes M., additional, de la Fuente, Adolfo, additional, Todisco, Elisabetta, additional, Gaidano, Gianluca, additional, Curti, Antonio, additional, Boissel, Nicolas, additional, Recher, Christian, additional, Schliemann, Christoph, additional, Sloss, Callum M, additional, Wang, Jiuzhou, additional, Malcolm, Kara E, additional, Zweidler-McKay, Patrick A, additional, and Sweet, Kendra, additional

Published
2021
Full Text
View/download PDF

43. In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present from the Diagnosis in Tiny Undetectable Subclones

Author

Avet-Loiseau, Herve, primary, Lannes, Romain, additional, Perrot, Aurore, additional, Mazzotti, Céline, additional, Divoux, Marion, additional, Cazaubiel, Titouan, additional, Leleu, Xavier, additional, Schavgoulidze, Anaïs, additional, Chretien, Marie-Lorraine, additional, Manier, Salomon, additional, Adiko, Didier, additional, Orsini-Piocelle, Frédérique, additional, Lifermann, Francois, additional, Brechignac, Sabine, additional, Gastaud, Lauris, additional, Bouscary, Didier, additional, Macro, Magaret, additional, Mohty, Mohamad, additional, Munshi, Nikhil C., additional, and Corre, Jill, additional

Published
2021
Full Text
View/download PDF

44. Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin

Author

Lambert, Juliette, primary, Peterlin, Pierre, additional, Pautas, Cecile, additional, Raffoux, Emmanuel, additional, Caillot, Denis, additional, Legrand, Ollivier, additional, Joris, Magalie, additional, Berceanu, Anna, additional, Malfuson, Jean Valere, additional, Chantepie, Sylvain, additional, Bernard, Marc, additional, Gastaud, Lauris, additional, Pigneux, Arnaud, additional, Benbrahim, Omar, additional, Bonmati, Caroline, additional, Mathilde, Hunault-Berger, additional, Dombret, Hervé, additional, Rousselot, Philippe, additional, Chevret, Sylvie, additional, and Castaigne, Sylvie, additional

Published
2021
Full Text
View/download PDF

45. Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study

Author

Lambert, Juliette, primary, Lambert, Jérôme, additional, Lemasle, Emilie, additional, Joris, Magalie, additional, Chantepie, Sylvain, additional, Pautas, Cecile, additional, Thomas, Xavier, additional, Malfuson, Jean Valere, additional, Gastaud, Lauris, additional, Caillot, Denis, additional, Tavernier, Emmanuelle, additional, Turlure, Pascal, additional, Carp, Diana, additional, Berthon, Celine, additional, Legrand, Olivier, additional, Marçais, Ambroise, additional, Vaida, Iona, additional, Barbieux, Sarah, additional, Rousselot, Philippe, additional, Gardin, Claude, additional, Terré, Christine, additional, Duployez, Nicolas, additional, Preudhomme, Claude, additional, Celli-Lebras, Karine, additional, Castaigne, Sylvie, additional, and Dombret, Herve, additional

Published
2021
Full Text
View/download PDF

46. Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia

Author

Daver, Naval, primary, Aribi, Ahmed, additional, Montesinos, Pau, additional, Roboz, Gail J., additional, Wang, Eunice S., additional, Walter, Roland B., additional, Jeyakumar, Deepa, additional, DeAngelo, Daniel J., additional, Erba, Harry P., additional, Advani, Anjali, additional, Burke, Patrick W., additional, Martinelli, Giovanni, additional, Gastaud, Lauris, additional, Thomas, Xavier, additional, Altman, Jessica K., additional, Mendez, Lourdes M., additional, de la Fuente, Adolfo, additional, Todisco, Elisabetta, additional, Gaidano, Gianluca, additional, Curti, Antonio, additional, Boissel, Nicolas, additional, Recher, Christian, additional, Schliemann, Christoph, additional, Konopleva, Marina, additional, Sallman, David A., additional, Torres, Laura, additional, Marcucci, Guido, additional, Kantarjian, Hagop, additional, Sloss, Callum M, additional, Malcolm, Kara E, additional, Zweidler-McKay, Patrick A, additional, and Sweet, Kendra, additional

Published
2021
Full Text
View/download PDF

47. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Author

Nathan, Paul, primary, Hassel, Jessica C., additional, Rutkowski, Piotr, additional, Baurain, Jean-Francois, additional, Butler, Marcus O., additional, Schlaak, Max, additional, Sullivan, Ryan J., additional, Ochsenreither, Sebastian, additional, Dummer, Reinhard, additional, Kirkwood, John M., additional, Joshua, Anthony M., additional, Sacco, Joseph J., additional, Shoushtari, Alexander N., additional, Orloff, Marlana, additional, Piulats, Josep M., additional, Milhem, Mohammed, additional, Salama, April K.S., additional, Curti, Brendan, additional, Demidov, Lev, additional, Gastaud, Lauris, additional, Mauch, Cornelia, additional, Yushak, Melinda, additional, Carvajal, Richard D., additional, Hamid, Omid, additional, Abdullah, Shaad E., additional, Holland, Chris, additional, Goodall, Howard, additional, and Piperno-Neumann, Sophie, additional

Published
2021
Full Text
View/download PDF

48. Orbital exenteration: an updated review with perspectives

Author

Martel, Arnaud, primary, Baillif, Stephanie, additional, Nahon-Esteve, Sacha, additional, Gastaud, Lauris, additional, Bertolotto, Corine, additional, Lassalle, Sandra, additional, Lagier, Jacques, additional, Hamedani, Mehrad, additional, and Poissonnet, Gilles, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results